CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing prevalence of bipolar disorder
4.1.2. Government initiatives and technological advancements
4.1.3. High demand for anti-depressants
4.1.4. Growing need to reduce the disease burden of bipolar disorder
4.1.5. Increase in treatment options for bipolar disorder
4.2. Market Restraints & Challenges
4.2.1. The dearth of proper diagnostic procedures for the identification of the disorder
4.2.2. Side effects associated with bipolar disorder therapeutics
4.2.3. Less number of approved anticonvulsants for the treatment of bipolar disorder
4.3. Market Opportunities
4.3.1. Advancements related to combination therapies of drugs
4.3.2. High potential in emerging economies
CHAPTER 5 GLOBAL BIPOLAR DISORDER MARKET – BY TYPE
5.1. Bipolar I disorder
5.2. Bipolar II disorder
CHAPTER 6 GLOBAL BIPOLAR DISORDER MARKET – BY DRUG CLASS
6.1. Mood stabiliser
6.2. Anticonvulsant
6.3. Antipsychotic drugs
6.4. Antidepressant drugs
6.5. Antianxiety drugs
CHAPTER 7 GLOBAL BIPOLAR DISORDER MARKET – BY MECHANISM OF
ACTION
7.1. Selective serotonin reuptake inhibitor
7.2. Serotonin norepinephrine reuptake inhibitor
7.3. Tricyclic antidepressants
7.4. Monoamine oxidase inhibitors
7.5. Benzodiazepines
7.6. Beta blockers
7.7. Others
CHAPTER 8 GLOBAL BIPOLAR DISORDER MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9 GLOBAL BIPOLAR DISORDER MARKET - COMPANY PROFILES
9.1. Abbott Laboratories
9.2. Bristol-Myers Squibb Company
9.3. AstraZeneca plc
9.4. Eli Lilly and Company
9.5. GlaxoSmithKline plc
9.6. Merck & Co., Inc.
9.7. Johnson & Johnson
9.8. Pfizer Inc.
9.9. Cephalon Inc.
9.10. Gedeon Richter plc
9.11. H. Lundbeck A/S
9.12. Otsuka America Pharmaceutical Inc.
9.13. Repligen Corporation
9.14. Validus Pharmaceuticals LLC
9.15. Allergen PLC
CHAPTER 10 GLOBAL BIPOLAR DISORDER MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11 MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12 APPENDIX
12.1. List of Tables
12.2. List of Figures
